Biblio Discovery — Demo Discovery Service

11 results for "Patrick Zueger"

Showing 1–11 · 0.98 seconds · RSS

  1. Journal Article

    Real-World Use and Effectiveness Outcomes in Patients with Rheumatoid Arthritis Treated with Upadacitinib: An Analysis from the CorEvitas Registry

    Joshua F. Baker; Patrick Zueger; Mira Ali et al.

    Rheumatology and Therapy, Vol. 11 No. 2 · 2024 · English · DOAJ Scopus

    Abstract Introduction Data assessing longer-term real-world effectiveness and treatment patterns with upadacitinib (UPA), a Janus kinase inhibitor, in rheumatoid arthritis (RA) are lacking. We assessed improvement in clinical and patient-reported outcomes and treatment patterns for up to 12 months…

  2. Journal Article

    Real-World Analysis of Initial Clinical Response and Future Outcomes Among Patients with Rheumatoid Arthritis Initiating and Remaining on a First-Line Tumor Necrosis Factor Inhibitor in the United States

    Christina Charles-Schoeman; Patrick Zueger; Erin McDearmon-Blondell et al.

    Rheumatology and Therapy, Vol. 13 No. 1 · 2025 · English · DOAJ Scopus

    Abstract Introduction This study aimed to evaluate a subsequent treatment response among patients with rheumatoid arthritis (RA) who initiated and remained on a first-line tumor necrosis factor inhibitor (TNFi) after achieving or not achieving an initial response. Methods This real-world…

  3. Journal Article

    Clinical and Economic Benefit of Achieving Disease Control in Psoriatic Arthritis and Ankylosing Spondylitis: A Retrospective Analysis from the OM1 Registry

    Martin J. Bergman; Patrick Zueger; Jayeshkumar Patel et al.

    Rheumatology and Therapy, Vol. 10 No. 1 · 2022 · English · DOAJ Scopus

    Abstract Background There is limited evidence on the clinical and economic benefit of achieving disease control in psoriatic arthritis (PsA) and ankylosing spondylitis (AS), thus we aimed to assess the impact of disease control on healthcare resource use (HCRU) and direct medical costs among US…

  4. Journal Article

    Real‐World Treatment and Care Patterns in Patients With Rheumatoid Arthritis Initiating First‐Line Tumor Necrosis Factor Inhibitor Therapy in the United States

    Colin Edgerton; Andrew Frick; Simon Helfgott et al.

    ACR Open Rheumatology, Vol. 6 No. 4 · 2024 · English · DOAJ Scopus

    Objective Treatment guidelines for rheumatoid arthritis (RA) recommend targeting low disease activity or remission and switching therapies for patients not reaching those targets. We evaluated real‐world use of disease activity measures, treatment discontinuation, and switching patterns among…

  5. Journal Article

    Site-specific resolution of enthesitis in patients with axial spondyloarthritis treated with tumor necrosis factor inhibitors

    Michael J. Nissen; Burkhard Möller; Adrian Ciurea et al.

    Arthritis Research & Therapy, Vol. 23 No. 1 · 2021 · English · DOAJ Scopus

    Abstract Background Enthesitis is a hallmark of spondyloarthritis (SpA) with a substantial impact on quality of life. Reports of treatment effectiveness across individual enthesitis sites in real-world patients with axial SpA (axSpA) are limited. We investigated the evolution of enthesitis…

  6. Journal Article

    Wearable activity tracker study exploring rheumatoid arthritis patients’ disease activity using patient-reported outcome measures, clinical measures, and biometric sensor data (the wear study)

    Laura Stradford; Jeffrey R. Curtis; Patrick Zueger et al.

    Contemporary Clinical Trials Communications, Vol. 38 · 2024 · English · DOAJ Scopus

    Background: Digital health studies using electronic patient reported outcomes (ePROs), wearables, and clinical data to provide a more comprehensive picture of patient health. Methods: Newly initiated patients on upadacitinib or adalimumab for RA will be recruited from community settings in the…

  7. Journal Article

    A Real-World Effectiveness Study Using a Mobile Application to Evaluate Early Outcomes with Upadacitinib in Rheumatoid Arthritis

    Leslie R. Harrold; Patrick Zueger; W. Benjamin Nowell et al.

    Rheumatology and Therapy, Vol. 10 No. 6 · 2023 · English · DOAJ Scopus

    Abstract Introduction The impact of upadacitinib on rheumatoid arthritis (RA) symptoms was evaluated during the first 12 weeks of treatment via patient-reported outcomes (PROs) using a mobile health application (app). Methods Participating rheumatologists from the CorEvitas RA Registry…

  8. Journal Article Full text

    Trial of Upadacitinib and Adalimumab for Psoriatic Arthritis

    Iain B. McInnes; Jaclyn K. Anderson; Marina Magrey et al.

    New England Journal of Medicine · 2021 · English · OpenAlex Scopus

    BACKGROUND: The Janus kinase inhibitor upadacitinib is a potential treatment for psoriatic arthritis. The efficacy and safety of upadacitinib as compared with adalimumab, a tumor necrosis factor α inhibitor, in patients who have an inadequate response to nonbiologic disease-modifying antirheumatic…

  9. Journal Article Full text

    Upadacitinib for psoriatic arthritis refractory to biologics: SELECT-PsA 2

    Philip J. Mease; Apinya Lertratanakul; Jaclyn K. Anderson et al.

    Annals of the Rheumatic Diseases · 2020 · English · OpenAlex Scopus

    BACKGROUND: Upadacitinib is a Janus kinase inhibitor under evaluation for the treatment of psoriatic arthritis (PsA). We evaluated upadacitinib in patients with PsA and prior inadequate response or intolerance to at least one biologic disease-modifying antirheumatic drug (DMARD). METHODS: In this…